ATE389719T1 - Behandlungsverfahren mit wisp-polypeptiden - Google Patents

Behandlungsverfahren mit wisp-polypeptiden

Info

Publication number
ATE389719T1
ATE389719T1 AT01987803T AT01987803T ATE389719T1 AT E389719 T1 ATE389719 T1 AT E389719T1 AT 01987803 T AT01987803 T AT 01987803T AT 01987803 T AT01987803 T AT 01987803T AT E389719 T1 ATE389719 T1 AT E389719T1
Authority
AT
Austria
Prior art keywords
administration
cartilage
treatment
injury
repair
Prior art date
Application number
AT01987803T
Other languages
English (en)
Inventor
Luc Desnoyer
Ellen Filvaroff
Diane Pennica
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE389719T1 publication Critical patent/ATE389719T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01987803T 2000-10-16 2001-10-12 Behandlungsverfahren mit wisp-polypeptiden ATE389719T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24122200P 2000-10-16 2000-10-16

Publications (1)

Publication Number Publication Date
ATE389719T1 true ATE389719T1 (de) 2008-04-15

Family

ID=22909763

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01987803T ATE389719T1 (de) 2000-10-16 2001-10-12 Behandlungsverfahren mit wisp-polypeptiden
AT08001040T ATE456655T1 (de) 2000-10-16 2001-10-12 Behandlungsverfahren unter verwendung von wisp- polypeptiden
AT10000199T ATE544855T1 (de) 2000-10-16 2001-10-12 Wisp polypeptide, und deren therapeutische anwendungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT08001040T ATE456655T1 (de) 2000-10-16 2001-10-12 Behandlungsverfahren unter verwendung von wisp- polypeptiden
AT10000199T ATE544855T1 (de) 2000-10-16 2001-10-12 Wisp polypeptide, und deren therapeutische anwendungen

Country Status (10)

Country Link
US (2) US7687460B2 (de)
EP (3) EP1326980B1 (de)
JP (1) JP4202128B2 (de)
AT (3) ATE389719T1 (de)
AU (2) AU2437702A (de)
CA (1) CA2425145C (de)
DE (2) DE60133301T2 (de)
ES (3) ES2304401T3 (de)
IL (3) IL155279A0 (de)
WO (1) WO2002033085A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE389719T1 (de) * 2000-10-16 2008-04-15 Genentech Inc Behandlungsverfahren mit wisp-polypeptiden
AU2004272066B8 (en) * 2003-09-11 2010-08-05 Genentech, Inc. Methods of using WISP antagonists
SE0401069D0 (sv) * 2004-04-26 2004-04-26 Anamar Medical Ab Use of Compounds for the Treatment of Diseases and Conditions
WO2007149328A1 (en) * 2006-06-20 2007-12-27 Genzyme Corporation Serum-free media and their uses for chondrocyte expansion
US8182998B2 (en) 2007-04-26 2012-05-22 Genera Istrazivanja D.O.O. Blood biomarkers for bone fracture and cartilage injury
CN101951938B (zh) * 2008-01-18 2016-04-13 伯纳姆医学研究所 内化rgd肽相关的方法和组合物
CA2766634A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
MX2012000707A (es) * 2009-07-14 2012-03-21 Scripps Research Inst Diferenciacion de celula madre mesenquimatica.
US20140037659A1 (en) * 2011-01-31 2014-02-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Snx9 as a novel biomarker for chronic inflammation and associated immunosuppresion and a new regulator of t cell receptor expression and function
BR112014019741A2 (pt) 2012-02-11 2020-12-22 Genentech, Inc Usos de um antagonista da via wnt, uso de uma terapia anticâncer, método de identificação de um indivíduo com câncer, métodos para prever, método de inibição da proliferação de uma célula de câncer, uso de um antagonista da translocação de r-spondina e antagonista da translocação de r-spondina isolado
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
WO2017207678A1 (en) * 2016-06-02 2017-12-07 Nestec S.A. Methods for treating sarcopenia and muscle injury
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
KR102167443B1 (ko) * 2019-03-25 2020-10-19 주식회사 카티프라임 체외 골관절염 모델 및 이를 이용한 골관절염 치료제 스크리닝 방법
CN111700881B (zh) * 2020-07-02 2021-05-18 四川大学 Wnt蛋白＼ZIF-8纳米复合体、其制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5408040A (en) 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
EP0736034A4 (de) 1993-12-22 1999-02-03 Merck & Co Inc Den wnt-x wachstumsfaktor kodierende dns
US5444047A (en) * 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
JP2001504336A (ja) 1996-11-08 2001-04-03 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 結合組織増殖因子―３
CA2294564A1 (en) * 1997-06-19 1998-12-23 Incyte Pharmaceuticals, Inc. Polynucleotides encoding a growth factor-like protein
US20020192209A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
ATE406441T1 (de) 1997-10-29 2008-09-15 Genentech Inc Verwendung des wnt-1 induzierten sekretierten polypeptids wisp-1
WO1999062927A1 (en) * 1998-06-05 1999-12-09 Human Genome Sciences, Inc. Connective tissue growth factor-4
KR100342045B1 (ko) * 1999-04-16 2002-06-27 김순택 2차전지
AU6088900A (en) * 1999-07-23 2001-02-13 Case Western Reserve University Novel methods and reagents useful in the treatment of osteoarthritis
GB9930768D0 (en) * 1999-12-29 2000-02-16 Pfizer Ltd Composition
US20020063763A1 (en) * 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
ATE389719T1 (de) * 2000-10-16 2008-04-15 Genentech Inc Behandlungsverfahren mit wisp-polypeptiden

Also Published As

Publication number Publication date
EP2180053B1 (de) 2012-02-08
EP1326980A2 (de) 2003-07-16
ATE456655T1 (de) 2010-02-15
WO2002033085A9 (en) 2002-07-25
ES2338492T3 (es) 2010-05-07
US20100093628A1 (en) 2010-04-15
EP1326980B1 (de) 2008-03-19
JP4202128B2 (ja) 2008-12-24
EP1927659A1 (de) 2008-06-04
US8138152B2 (en) 2012-03-20
ES2381935T3 (es) 2012-06-01
EP1927659B1 (de) 2010-01-27
US7687460B2 (en) 2010-03-30
IL200484A (en) 2012-05-31
AU2002224377B8 (en) 2002-04-29
IL155279A (en) 2011-05-31
EP2180053A3 (de) 2010-11-10
IL155279A0 (en) 2003-11-23
AU2002224377B2 (en) 2007-07-19
EP2180053A2 (de) 2010-04-28
WO2002033085A3 (en) 2003-04-17
CA2425145C (en) 2011-08-30
ATE544855T1 (de) 2012-02-15
US20050054563A1 (en) 2005-03-10
DE60133301D1 (de) 2008-04-30
IL200484A0 (en) 2010-04-29
JP2004534720A (ja) 2004-11-18
AU2437702A (en) 2002-04-29
WO2002033085A2 (en) 2002-04-25
CA2425145A1 (en) 2002-04-25
DE60141236D1 (de) 2010-03-18
ES2304401T3 (es) 2008-10-16
DE60133301T2 (de) 2009-05-14

Similar Documents

Publication Publication Date Title
IL200484A0 (en) Use of wisp polypeptides wisp for the preparation of medicaments
IL151408A0 (en) Use of insulin for the treatment of cartilagenous disorders
DE69433742D1 (de) Bmp-10 zusammensetzungen
ATE362766T1 (de) Apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dislipidemischer erkrankungen
DE69729125D1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
DE69835810D1 (de) Osteogene vorrichtungen und verfahren zu ihrer verwendung zur knochenreparatur
DK1378572T3 (da) BMP-11-sammensætninger
ES2182902T3 (es) Sistema de reparacion de superficies de articulaciones.
ATE390142T1 (de) Synergistische zusammensetzung zur behandlung von diabetes mellitus
PT807633E (pt) Novas pirimidin-4-onas substituidas em 2,3, e fundidas com heteroarilo em (5,6)
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
DE69821793D1 (de) Neuronale verwendungen des bmp-11
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
IT1293305B1 (it) Sali di acidi difosfonici e loro impiego farmacologico nel trattamento dell'osteoporosi
SE8902042D0 (sv) Treatment of arthritis
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
DK0918455T3 (da) Anvendelse af galanin til reparation af nerveskader
DE69941134D1 (de) Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1326980

Country of ref document: EP